Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP)

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 8, 2014, Pages 767-776

  Hannon, Tamara S ^a   Kirkman, M S ^b   Patel, Yash R ^c   Considine, Robert V ^a   Mather, Kieren J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c ST JOSEPH MERCY HOSPITAL   (United States)

Author keywords

Acarbose; Hyperglycaemic clamp; Insulin; Obesity; Oral glucose tolerance test

Indexed keywords

ACARBOSE; GLUCOSE; INSULIN; PLACEBO; GLYCOSIDASE INHIBITOR;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; TREATMENT OUTCOME; WEIGHT REDUCTION; BLOOD; BODY MASS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DIET THERAPY; DISEASE COURSE; DRUG EFFECTS; EARLY DIAGNOSIS; LIFESTYLE; LOW CALORY DIET; MASS SCREENING; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS);

ACARBOSE; ADULT; BODY MASS INDEX; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DIET, REDUCING; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; LIFE STYLE; MALE; MASS SCREENING; MIDDLE AGED; OBESITY; OVERWEIGHT; PATIENT EDUCATION AS TOPIC; WEIGHT LOSS;

EID: 84910600265     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2553     Document Type: Article

References (26)

1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46(1): 3-19.
2. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116(7): 1802-1812.
3. Kirkman MS, Shankar RR, Shankar S, et al. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the early diabetes intervention program. Diabetes Care 2006; 29(9): 2095-2101.
4. Nijpels G, Boorsma W, Dekker JM, Kostense PJ, Bouter LM, Heine RJ. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI). Diabetes Metab Res Rev 2008; 24(8): 611-616.
5. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237(3): E214-E223.
6. Kahn SE, Porte D Jr. Islet dysfunction in non-insulin-dependent diabetes mellitus. Am J Med 1988; 85(5A): 4-8.
7. Mitrakou A, Vuorinen-Markkola H, Raptis G, et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp. J Clin Endocrinol Metab 1992; 75(2): 379-382.
8. Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care 2010; 33(10): 2225-2231.
9. Elbein SC, Wegner K, Kahn SE. Reduced beta-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care 2000; 23(2): 221-227.
10. Kahn SE, Montgomery B, Howell W, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86(12): 5824-5829.
11. Giannini C, Weiss R, Cali A, et al. Evidence for early defects in insulin sensitivity and secretion before the onset of glucose dysregulation in obese youths: a longitudinal study. Diabetes 2012; 61(3): 606-614.
12. Kanat M, Winnier D, Norton L, et al. The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. Diabetes Care 2011; 34(4): 1006-1010.
13. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373(9682): 2215-2221.
14. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78(3): 305-312.
15. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393-403.
16. Basu R, Barosa C, Jones J, et al. Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia. J Clin Endocrinol Metab 2013; 98(3): E409-E417.
17. Bock G, Dalla Man C, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006; 55(12): 3536-3549.
18. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359(9323): 2072-2077.
19. Bunck MC, Corner A, Eliasson B, et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011; 34(9): 2041-2047.
20. Derosa G, Franzetti IG, Querci F, et al. Exenatide plus metformin compared with metformin alone on beta-cell function in patients with Type 2 diabetes. Diabet Med J Br Diabet Assoc 2012; 29(12): 1515-1523.
21. DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011; 34(Suppl 2): S202-S209.
22. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371(9626): 1753-1760.
23. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. Beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012; 35(7): 1406-1412.
24. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009; 32(Suppl 2): S151-S156.
25. Garber AJ. Incretin effects on beta-cell function, replication, and mass: the human perspective. Diabetes Care 2011; 34(Suppl 2): S258-S263.
26. Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, noninferiority randomised trial. Lancet Diabet Endocrinol 2014; 2(1):46-55.